• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FDA 批准的人工智能和基于机器学习的医疗器械及其 510(k) 前序网络。

FDA-cleared artificial intelligence and machine learning-based medical devices and their 510(k) predicate networks.

机构信息

Institute for Diagnostic and Interventional Radiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Nuclear Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Institute for Diagnostic and Interventional Radiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Center for Artificial Intelligence in Medicine and Imaging, Stanford University, Stanford, CA, USA.

出版信息

Lancet Digit Health. 2023 Sep;5(9):e618-e626. doi: 10.1016/S2589-7500(23)00126-7.

DOI:10.1016/S2589-7500(23)00126-7
PMID:37625896
Abstract

The US Food and Drug Administration is clearing an increasing number of artificial intelligence and machine learning (AI/ML)-based medical devices through the 510(k) pathway. This pathway allows clearance if the device is substantially equivalent to a former cleared device (ie, predicate). We analysed the predicate networks of cleared AI/ML-based medical devices (cleared between 2019 and 2021), their underlying tasks, and recalls. More than a third of cleared AI/ML-based medical devices originated from non-AI/ML-based medical devices in the first generation. Devices with the longest time since the last predicate device with an AI/ML component were haematology (2001), radiology (2001), and cardiovascular devices (2008). Especially for devices in radiology, the AI/ML tasks changed frequently along the device's predicate network, raising safety concerns. To date, only a few recalls might have affected the AI/ML components. To improve patient care, a stronger focus should be placed on the distinctive characteristics of AI/ML when defining substantial equivalence between a new AI/ML-based medical device and predicate devices.

摘要

美国食品和药物管理局正在通过 510(k)途径越来越多地批准人工智能和机器学习 (AI/ML) 为基础的医疗设备。如果该设备与以前已批准的设备(即前导设备)基本等效,则可以通过该途径获得批准。我们分析了已批准的基于 AI/ML 的医疗设备的前导网络(在 2019 年至 2021 年期间获得批准)、其基础任务和召回情况。超过三分之一的已批准的基于 AI/ML 的医疗设备来自第一代非 AI/ML 为基础的医疗设备。具有 AI/ML 组件的最后一个前导设备以来时间最长的设备是血液学(2001 年)、放射学(2001 年)和心血管设备(2008 年)。特别是对于放射学设备,AI/ML 任务在前导网络中经常发生变化,引起了安全问题。迄今为止,可能只有少数召回事件影响了 AI/ML 组件。为了改善患者护理,在定义新的基于 AI/ML 的医疗设备与前导设备之间的实质性等效性时,应更加关注 AI/ML 的独特特征。

相似文献

1
FDA-cleared artificial intelligence and machine learning-based medical devices and their 510(k) predicate networks.FDA 批准的人工智能和基于机器学习的医疗器械及其 510(k) 前序网络。
Lancet Digit Health. 2023 Sep;5(9):e618-e626. doi: 10.1016/S2589-7500(23)00126-7.
2
Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance.医疗器械获得 510(k) 许可后与召回相关的监管提交特征。
JAMA. 2023 Jan 10;329(2):144-156. doi: 10.1001/jama.2022.22974.
3
The 2021 landscape of FDA-approved artificial intelligence/machine learning-enabled medical devices: An analysis of the characteristics and intended use.2021 年美国食品药品监督管理局批准的人工智能/机器学习医疗器械全景:特征和预期用途分析。
Int J Med Inform. 2022 Sep;165:104828. doi: 10.1016/j.ijmedinf.2022.104828. Epub 2022 Jul 1.
4
Mapping the genealogy of medical device predicates in the United States.绘制美国医疗器械谓词的谱系图。
PLoS One. 2021 Oct 7;16(10):e0258153. doi: 10.1371/journal.pone.0258153. eCollection 2021.
5
Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): a comparative analysis.美国和欧洲对人工智能和基于机器学习的医疗器械的审批(2015-20):比较分析。
Lancet Digit Health. 2021 Mar;3(3):e195-e203. doi: 10.1016/S2589-7500(20)30292-2. Epub 2021 Jan 18.
6
The regulatory environment for artificial intelligence-enabled devices in the United States.美国人工智能设备的监管环境。
Semin Vasc Surg. 2023 Sep;36(3):435-439. doi: 10.1053/j.semvascsurg.2023.05.005. Epub 2023 May 27.
7
The Complex Process of Using the Interconnected Knee Arthroplasty Device Clearance Pathway.使用相互关联的膝关节置换装置间隙通路的复杂过程。
HSS J. 2022 Nov;18(4):462-468. doi: 10.1177/15563316221099014. Epub 2022 Jun 20.
8
Marketing and US Food and Drug Administration Clearance of Artificial Intelligence and Machine Learning Enabled Software in and as Medical Devices: A Systematic Review.营销与美国食品和药物管理局对人工智能和机器学习在医疗器械中的应用和授权软件的审批:系统评价。
JAMA Netw Open. 2023 Jul 3;6(7):e2321792. doi: 10.1001/jamanetworkopen.2023.21792.
9
Trends in clinical validation and usage of US Food and Drug Administration-cleared artificial intelligence algorithms for medical imaging.美国食品药品监督管理局批准的用于医学成像的人工智能算法的临床验证和使用趋势。
Clin Radiol. 2023 Feb;78(2):123-129. doi: 10.1016/j.crad.2022.09.122. Epub 2022 Oct 28.
10
Mature artificial intelligence- and machine learning-enabled medical tools impacting vascular surgical care: A scoping review of late-stage, US Food and Drug Administration-approved or cleared technologies relevant to vascular surgeons.成熟的人工智能和机器学习支持的医疗工具对血管外科技师护理的影响:对与血管外科技师相关的晚期、美国食品和药物管理局批准或清除的技术进行的范围审查。
Semin Vasc Surg. 2023 Sep;36(3):460-470. doi: 10.1053/j.semvascsurg.2023.06.001. Epub 2023 Jun 26.

引用本文的文献

1
Systematic review and meta-analysis of artificial intelligence for image-based lung cancer classification and prognostic evaluation.基于图像的肺癌分类与预后评估中人工智能的系统评价与荟萃分析。
NPJ Precis Oncol. 2025 Aug 26;9(1):300. doi: 10.1038/s41698-025-01095-1.
2
Early Recalls and Clinical Validation Gaps in Artificial Intelligence-Enabled Medical Devices.人工智能医疗设备的早期召回与临床验证差距
JAMA Health Forum. 2025 Aug 1;6(8):e253172. doi: 10.1001/jamahealthforum.2025.3172.
3
Artificial intelligence in pediatric healthcare: current applications, potential, and implementation considerations.
人工智能在儿科医疗保健中的应用:当前应用、潜力及实施考量
Clin Exp Pediatr. 2025 Sep;68(9):641-651. doi: 10.3345/cep.2025.00962. Epub 2025 Jun 25.
4
The state of the art in artificial intelligence and digital pathology in prostate cancer.前列腺癌人工智能与数字病理学的最新进展。
Nat Rev Urol. 2025 Aug 4. doi: 10.1038/s41585-025-01070-2.
5
Machine learning enables legal risk assessment in internet healthcare using HIPAA data.机器学习可利用《健康保险流通与责任法案》(HIPAA)数据对互联网医疗中的法律风险进行评估。
Sci Rep. 2025 Aug 5;15(1):28477. doi: 10.1038/s41598-025-13720-x.
6
United States Food and Drug Administration Regulation of Clinical Software in the Era of Artificial Intelligence and Machine Learning.美国食品药品监督管理局对人工智能和机器学习时代临床软件的监管
Mayo Clin Proc Digit Health. 2025 May 27;3(3):100231. doi: 10.1016/j.mcpdig.2025.100231. eCollection 2025 Sep.
7
Which explanations do clinicians prefer? A comparative evaluation of XAI understandability and actionability in predicting the need for hospitalization.临床医生更喜欢哪些解释?对XAI在预测住院需求方面的可理解性和可操作性的比较评估。
BMC Med Inform Decis Mak. 2025 Jul 16;25(1):269. doi: 10.1186/s12911-025-03045-0.
8
Regulatory Insights From 27 Years of Artificial Intelligence/Machine Learning-Enabled Medical Device Recalls in the United States: Implications for Future Governance.美国27年人工智能/机器学习驱动的医疗器械召回监管洞察:对未来治理的启示
JMIR Med Inform. 2025 Jul 11;13:e67552. doi: 10.2196/67552.
9
How AI is used in FDA-authorized medical devices: a taxonomy across 1,016 authorizations.人工智能在获得美国食品药品监督管理局授权的医疗设备中的应用:对1016项授权的分类。
NPJ Digit Med. 2025 Jul 1;8(1):388. doi: 10.1038/s41746-025-01800-1.
10
A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma.一种预测免疫检查点抑制剂对不可切除肝细胞癌生存获益的多模态融合系统。
NPJ Precis Oncol. 2025 Jun 14;9(1):185. doi: 10.1038/s41698-025-00979-6.